Denosumab: The Most Effective Treatment for Osteoporosis?

Our study found that different interventions for osteoporosis have varying efficacy over time. Alendronate's effectiveness decreased over time, possibly due to tolerance or bone remodeling. Clodronate had a higher absorption rate and showed greater efficacy at 12 months compared to 6 months. Zoledronate, a long-acting bisphosphonate, had stable effects throughout the study.

However, we recommend denosumab as the preferred option. It has been shown to increase bone density for up to 10 years with minimal side effects. Switching from oral bisphosphonates to denosumab has also been associated with significant improvements in postmenopausal osteoporosis patients.

Teriparatide stimulates bone formation and may be better than alendronate for improving bone mineral density. Raloxifene, a selective estrogen receptor modulator, can also increase bone density in postmenopausal women. However, denosumab is more widely applicable and has been shown to reduce the risk of death and ischemic stroke in women with osteoporosis.

Previous studies have shown that both denosumab and zoledronate reduce periprosthetic bone mineral density loss after hip replacement surgery. Denosumab has been ranked as the optimal choice for improving total hip bone mineral density in postmenopausal women.

In conclusion, our study provides important insights into the efficacy of different interventions for osteoporosis. Denosumab emerges as the recommended option due to its long-term effectiveness and low incidence of adverse events.